Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

TRIANGLE PHARMACEUTICALS INC

Form 8-K January 07, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 6, 2003

TRIANGLE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 000-21589 56-1930728

(State or other (Commission (IRS Employer jurisdiction File Number) Identification No.) of incorporation)

4 University Place, 4611 University Drive, Durham, North Carolina 27707

4 University Flace, 4011 University Drive, Durham, North Carolina 27707

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (919) 493-5980

(Former name or former address, if changed since last report)

Item 5. Other Events

On January 6, 2003, Triangle Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

- (c) Exhibits. The following document is incorporated by reference to this Report:
 - 99.1 Press release dated January 6, 2003.

SIGNATURES

Edgar Filing: TRIANGLE PHARMACEUTICALS INC - Form 8-K

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Triangle Pharmaceuticals, Inc.

(Registrant)

January 7, 2003

/s/ Andrew Finkle

Date

(Signature)

Name: Andrew Finkle

Title: Executive Vice President and General

Counsel